The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

Blood

Volumn 123, Issue 7, 2014, Pages 1032-1039

  Hoellenriegel, Julia ^a   Zboralski, Dirk ^b   Maasch, Christian ^b   Rosin, Nathalie Y ^a   Wierda, William G ^a   Keating, Michael J ^a   Kruschinski, Anna ^b   Burger, Jan A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NOXXON PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BENDAMUSTINE; CHEMOKINE RECEPTOR ANTAGONIST; FLUDARABINE; HEPARIN; NOX A 12; NOX A12; RNA; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APTAMER; CXCL12 PROTEIN, HUMAN; NOX-A12; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; B-CELL LEUKEMIA CELL LINE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL MIGRATION; CELL MOTILITY; CELL SURFACE; CHEMOSENSITIZATION; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIZATION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; STROMA CELL; CELL CULTURE; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; LEUKEMIA CELL LINE; LYMPHOCYTE; MESENCHYMAL STROMA CELL; PATHOLOGY; PHYSIOLOGY; TRANSCELLULAR CELL MIGRATION;

ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CXCL12; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; JURKAT CELLS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; MESENCHYMAL STROMAL CELLS; RECOMBINANT PROTEINS; TRANSCELLULAR CELL MIGRATION;

EID: 84897880564     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-493924     Document Type: Article

References (24)

1. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
2. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005;106(3):1012- 1020. (Pubitemid 41076448)
3. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol. 2002;32(5):1403-1413. (Pubitemid 34546268)
4. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23(1):43-52.
5. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461-466. (Pubitemid 34232911)
6. Fecteau JF, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013;121(6):971-974.
7. Amara A, Lorthioir O, Valenzuela A, et al. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 1999;274(34):23916-23925.
8. Sapay N, Cabannes E, Petitou M, Imberty A. Molecular modeling of the interaction between heparan sulfate and cellular growth factors: bringing pieces together. Glycobiology. 2011;21(9):1181-1193.
9. Rueda P, Richart A, Récalde A, et al. Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions. Circulation. 2012;126(15):1882-1895.
10. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91(7):2387-2396.
11. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441-4450.
12. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999;94(11):3658-3667.
13. Hiai H, Nishi Y, Miyazawa T, Matsudaira Y, Nishizuka Y. Mouse lymphoid leukemias: symbiotic complexes of neoplastic lymphocytes and their microenvironments. J Natl Cancer Inst. 1981;66(4):713-722. (Pubitemid 11101043)
14. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA. 1994;91(6):2305-2309. (Pubitemid 24092092)
15. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005;106(5):1824-1830. (Pubitemid 41208600)
16. O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS ONE. 2010;5(7):e11716.
17. Andritsos L, Byrd JC, Jones JA, et al. Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. Blood. 2010;116(21):1017a.
18. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 2012;21(3):341-353.
19. Vater A, Klussmann S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr Opin Drug Discov Devel. 2003;6(2):253-261. (Pubitemid 36368380)
20. Klussmann S, Nolte A, Bald R, Erdmann VA, Fürste JP. Mirror-image RNA that binds D-adenosine. Nat Biotechnol. 1996;14(9):1112-1115. (Pubitemid 26299110)
21. Eulberg D, Klussmann S. Spiegelmers: biostable aptamers. ChemBioChem. 2003;4(10):979-983. (Pubitemid 37267585)
22. Vater A, Sahlmann J, Kröger N, et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther. 2013;94(1):150-157.
23. Hoffmann S, Hoos J, Klussmann S, Vonhoff S. RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation. Curr Protoc Nucleic Acid Chem. 2011;Unit 4.46:1-30.
24. Gobbi M, Caligaris-Cappio F, Montillo M, et al. Phase IIa study of the anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 alone and combined with bendamustine/rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2012;120(21): Abstract 4593.